Elixxer

Elixxer Tangible Book Value per Share

The Tangible Book Value per Share of Elixxer (ELXR.H.V) as of Oct 27, 2026 is -0.10 CAD. In the previous year, Tangible Book Value per Share was -0.06 CAD — a change of 71.90% (lower).

Tangible Book Value per Share

-0.10CAD

YoY

71.90%

Last updated:

Tangible Book Value per Share of Elixxer is 2023 -0.10 CAD. Tangible Book Value per Share of Elixxer was 2022 -0.06 CAD. It decreases by 71.90% lower compared to the previous year.

The Elixxer Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2016
0.08 CAD
Jan 1, 2017
0.02 CAD
Jan 1, 2018
0.19 CAD
Jan 1, 2019
0.14 CAD
Jan 1, 2020
0.05 CAD
Jan 1, 2021
0.09 CAD
Jan 1, 2022
-0.06 CAD
Jan 1, 2023
-0.10 CAD
The Elixxer Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
-0.10CAD+71.90%
-0.06CAD-166.64%
0.09CAD+76.12%
0.05CAD-63.89%
0.14CAD-25.43%
0.19CAD+1,021.23%
0.02CAD-79.12%
0.08CAD+69,817.59%
0.00CAD-97.57%
0.00CAD-44.50%
0.01CAD—
0.00CAD-100.00%
0.13CAD-4.89%
0.14CAD+4.34%
0.13CAD-2,403.51%
-0.01CAD-670.00%
0.00CAD-95.98%
0.02CAD-76.53%
0.11CAD-682.97%
-0.02CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elixxer stock

Tangible Book Value per Share of Elixxer is -0.10 CAD in 2023.

Tangible Book Value per Share of Elixxer changed from -0.06 CAD to -0.10 CAD, representing a 71.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Elixxer since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Elixxer

All Key Metrics — Elixxer